Baxter International (BAX) vs ResMed (RMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Baxter International (BAX) has outperformed ResMed (RMD) over the past year, gaining 5.1% versus a loss of 19.7%. Over five years, RMD leads with a -11.3% price change compared with -70.0% for BAX. ResMed is the larger company by market cap ($31.89 billion vs $12.36 billion), about 2.6 times the size.
On valuation, Baxter International trades at a lower forward P/E (11.7x vs 17.1x for ResMed). ResMed offers the higher dividend yield (1.06% vs 0.84%). ResMed converts more of its revenue into profit, with a net margin of 26.9% versus -8.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BAX | RMD |
|---|---|---|
| Share price | $23.90 | $226.73 |
| Market cap | $12.36B | $31.89B |
| 1-day change | -0.29% | +0.33% |
| YTD return | +25.07% | -5.87% |
| 1-year return | +5.05% | -19.70% |
| 5-year return | -70.01% | -11.26% |
| P/E ratio (TTM) | — | 21.74 |
| Forward P/E | 11.72 | 17.14 |
| EPS (TTM) | $-1.88 | $10.43 |
| Dividend yield | 0.84% | 1.06% |
| Annual dividend | $0.20 | $2.40 |
| Revenue (latest FY) | $11.24B | $5.65B |
| Revenue growth (YoY) | +5.72% | +9.85% |
| Net income (latest FY) | $-957.00M | $1.52B |
| Gross margin | 30.05% | 61.06% |
| Operating margin | -2.74% | 33.37% |
| Net margin | -8.51% | 26.94% |
| 52-week high | $30.00 | $277.85 |
| 52-week low | $15.73 | $180.27 |
| Distance from 52-week high | -20.33% | -18.40% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +16.82% | +10.36% |
| Average volume | 6.66M | 1.33M |
| Shares outstanding | 517.00M | 140.64M |
| Employees | 37,500 | 11,370 |
| Sector | Healthcare | Health Care |
| Industry | Medical Instruments & Supplies | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ResMed is about 2.6 times larger than Baxter International by market value ($31.89B vs $12.36B).
- BAX has outperformed RMD by 24.8 percentage points over the past year.
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus -8.5 cents for Baxter International.
- The two companies sit in different sectors: Baxter International in Healthcare and ResMed in Health Care.
About Baxter International
BAX stock →Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Healthcare · Medical Instruments & Supplies · 37,500 employees
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
BAX vs RMD FAQ
Which is bigger, Baxter International or ResMed?
ResMed (RMD) is larger, with a market capitalization of $31.89B compared with $12.36B for Baxter International (BAX).
Which stock has performed better over the past year, BAX or RMD?
BAX returned +5.05% over the past 12 months, compared with -19.70% for RMD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Baxter International or ResMed?
ResMed has the higher yield at 1.06%, compared with 0.84% for Baxter International.
Are Baxter International and ResMed in the same industry?
No. Baxter International is in the Healthcare sector, while ResMed is in Health Care.